Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients

Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients

Lymphoma is a cancer that begins in the lymphocyte cells of the immune system. There are over 60 different types, broadly grouped into Hodgkin lymphomas and non-Hodgkin lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma. The primary treatment for DLBCL...

Full description

Saved in:
Bibliographic Details
Main Author: Vijay, Varsheni
Other Authors: Li Yinghui
Format: Student Research Poster
Language:English
Published: Nanyang Technological University 2023
Subjects:
Science::Biological sciences
Online Access:https://hdl.handle.net/10356/170727
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-170727
record_format dspace
spelling sg-ntu-dr.10356-1707272023-10-02T15:39:30Z Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients Vijay, Varsheni Li Yinghui School of Biological Sciences liyh@ntu.edu.sg Science::Biological sciences Lymphoma is a cancer that begins in the lymphocyte cells of the immune system. There are over 60 different types, broadly grouped into Hodgkin lymphomas and non-Hodgkin lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma. The primary treatment for DLBCL is R-CHOP (Rituximab, Cyclophosphamide, doxorubicin hydrochloride (Hydroxy daunomycin), Oncovin, and Prednisone) chemotherapy. However, even after the treatment, only 50-60% of patients show complete response; the remaining patients suffer from progression in the form of relapse (cancer reappearing) and refractory disease (cancer stops responding to treatment). 2023-09-27T12:55:15Z 2023-09-27T12:55:15Z 2022 Student Research Poster Vijay, V. (2022). Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients. Student Research Poster, Nanyang Technological University, Singapore. https://hdl.handle.net/10356/170727 https://hdl.handle.net/10356/170727 en © 2022 The Author(s). application/pdf Nanyang Technological University
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Science::Biological sciences
spellingShingle Science::Biological sciences
Vijay, Varsheni
Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients
description Lymphoma is a cancer that begins in the lymphocyte cells of the immune system. There are over 60 different types, broadly grouped into Hodgkin lymphomas and non-Hodgkin lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma. The primary treatment for DLBCL is R-CHOP (Rituximab, Cyclophosphamide, doxorubicin hydrochloride (Hydroxy daunomycin), Oncovin, and Prednisone) chemotherapy. However, even after the treatment, only 50-60% of patients show complete response; the remaining patients suffer from progression in the form of relapse (cancer reappearing) and refractory disease (cancer stops responding to treatment).
author2 Li Yinghui
author_facet Li Yinghui
Vijay, Varsheni
format Student Research Poster
author Vijay, Varsheni
author_sort Vijay, Varsheni
title Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients
title_short Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients
title_full Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients
title_fullStr Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients
title_full_unstemmed Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients
title_sort identifying gene signatures contributing to progression after chemotherapy in dlbcl patients
publisher Nanyang Technological University
publishDate 2023
url https://hdl.handle.net/10356/170727
_version_ 1779156742645481472

Similar Items